Amelioration of XXXX of @entity161 by @entity1063 reuptake inhibitor.

@entity1 @entity308 @entity1109 @entity18891 @entity51 @entity161 @entity1767 @entity1063
OBJECTIVE: Negative symptoms are a significant barrier to successful functional outcome and recovery in individuals with @entity161 and their management is not unproblematic. @entity18891 is a @entity1063 reuptake inhibitor (NRI). Previous studies regarding the useful effects of @entity18891 on deficit symptoms of @entity161 have resulted in inconsistent results. The present study therefore evaluated the effectiveness of @entity18891 as an adjunctive treatment in a group of @entity161 @entity1 with prominent negative symptoms. METHOD: A total of 50 male inpatients meeting diagnosis of @entity161 entered into a 12-week parallel group, double-blind study for random assignment to @entity18891 (n = 25 @entity1 ) or placebo (n = 25 @entity1 ). The inclusion criterion, in addition to the diagnosis of @entity161 , was the existence of obvious negative symptoms for a duration of at least 2 years. The Scale for Assessment of Negative Symptoms (SANS) was used as the primary outcome measure. The @entity1109 ( @entity1109 ), Simpson Angus Scale (SAS), Hamilton Rating Scale for @entity308 (HAM-D) and Mini-Mental Status Examination (MMSE) were used for comparison of the intervening parameters in this study. RESULTS: According to the findings, 76% of @entity1 in the target group showed some positive response to @entity18891 compared with 24% in the control group (p < 0.01). The mean total score of SANS in the @entity18891 group decreased significantly from 79.94    1.20 to 74.23    4.07 (p < 0.0001) at the end of the study; such an improvement was not significant in the placebo group with a decrease from 80.42    2.46 to 79.08    5.83 (p < 0.29). Changes of @entity1109 were insignificant in both groups. Effect size analysis for changes of SANS at the end of assessment indicated a large improvement with @entity18891 (Cohen's d = 2.91). CONCLUSION: @entity18891 , as an adjuvant to @entity1767 , may have a helpful effect on the @entity51 of @entity161 .
